DermTech, Inc.
DMTKQ · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.01 | -0.22 | 0.64 |
| FCF Yield | -143.73% | -185.38% | -14.20% | -5.54% |
| EV / EBITDA | -0.73 | -0.27 | -3.83 | -15.14 |
| Quality | ||||
| ROIC | -92.98% | -62.79% | -32.56% | -54.74% |
| Gross Margin | 1.80% | 4.46% | 10.76% | -1.63% |
| Cash Conversion Ratio | 0.76 | 0.82 | 0.79 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.92% | 35.12% | 52.10% | – |
| Free Cash Flow Growth | 20.99% | -52.05% | -112.42% | -69.54% |
| Safety | ||||
| Net Debt / EBITDA | -0.18 | 0.19 | 2.25 | 0.69 |
| Interest Coverage | -20,747.80 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 14.96 | 7.89 | 22.01 | 57.51 |
| Cash Conversion Cycle | 50.00 | 98.81 | 35.69 | 2.14 |